Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28367798 | 0.98 | BTK (0.35) | BTKGAAMEN1MAPK1KMT2A | |
| SCHEMBL27575292 | 0.95 | BTK (0.36) | BTKGAAMEN1MAPK1KMT2A | |
| SCHEMBL14908805 | 0.91 | MEN1 (0.37) | BTKGAAMEN1MAPK1KMT2A | |
| SCHEMBL27795461 | 0.84 | KMT2A (0.33) | BTKGAAMEN1MAPK1KMT2A | |
| SCHEMBL29069892 | 0.82 | BTK (0.31) | BTKMEN1MAPK1KMT2ACTSL | |
| SCHEMBL27564556 | 0.81 | CA12 (0.34) | BTKGAAMEN1MAPK1KMT2A | |
| SCHEMBL2333417 | 0.81 | BTK (0.36) | BTKGAAMEN1MAPK1KMT2A | |
| SCHEMBL29069727 | 0.81 | BTK (0.36) | BTKGAAMEN1MAPK1KMT2A | |
| SCHEMBL9936616 | 0.81 | BTK (0.36) | BTKGAAMEN1MAPK1KMT2A | |
| SCHEMBL6245659 | 0.81 | GAA (0.33) | BTKGAAMEN1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118139868-A | Orally bioavailable nucleoside analogs | 维纳拓尔斯制药公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-114681443-B | Nitrile-containing antiviral compounds | 辉瑞大药厂 | 2024-05-10 | — | — | CN | disclosed |
| US-20240124456-A1 | AZA-ERGOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2024-04-18 | — | — | US | disclosed |
| EP-4286384-A1 | AZA-ERGOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ShanghaiTech University (CN) | 2023-12-06 | — | — | EP | disclosed |
| CN-114835709-A | Aza-ergoline derivative and preparation method and application thereof | 上海科技大学 | 2022-08-02 | — | — | CN | disclosed |
| CN-114681443-A | Nitrile-containing antiviral compounds | 辉瑞大药厂 | 2022-07-01 | — | — | CN | disclosed |
| CN-114466838-A | Nitrile-containing antiviral compounds | 辉瑞大药厂 | 2022-05-10 | — | — | CN | disclosed |
| CN-110769821-A | Spirocyclic indolines as IL-17 modulators | UCB生物制药私人有限公司 | 2020-02-07 | — | — | CN | disclosed |
| US-9133104-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | disclosed |
| US-20130116318-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| EP-1879895-B1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2011-06-08 | — | — | EP | disclosed |
| US-7939666-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-05-10 | — | — | US | disclosed |
| EP-2301939-A1 | Enzyme inhibitors | Chroma Therapeutics Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| WO-2011016576-A1 | ALANINE DERIVATIVES AS INHIBITORS OF APOPTOSIS PROTEINS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | WO | disclosed |
| US-20090291978-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | US | disclosed |
| EP-0471280-B1 | Trans-2-acylaminocyclohexyloxyacyldipeptides | UNIV LJUBLJANI (YU) | 1996-11-06 | — | — | EP | disclosed |
| US-5231216-A | Trans-2-acylaminocyclohexyloxyacyldipeptides in the form of mixtures of diastereoisomers thereof and in the form of pure diasteredisomers, process for the preparation thereof and pharmaceutical compositions containing the same | UNIVERZA EDVARDA KARDELJA V LJUBLJANA (YU) | 1993-07-27 | — | — | US | disclosed |
| EP-0471280-A2 | Trans-2-acylaminocyclohexyloxyacyldipeptides | UNIVERZA EDVARDA KARDELJA V LJUBLJANI, VDO FAKULTETA ZA NARAVOSLOVJE IN TEHNOLOGIJO, N.SOL.O., LUBLJANA (YU) | 1992-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116318-A1 | Enzyme Inhibitors | HDAC1, HDAC11, HDAC7 | BTK 3920/4885GAA 34/4885MEN1 2620/4885 |
| US-20240124456-A1 | AZA-ERGOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ERG, CHRNA7, CHRNA5 | BTK 4786/4885GAA 2231/4885MEN1 1366/4885 |
| US-20140163042-A1 | ENZYME INHIBITORS | HAT1, NR2E1, HDAC3 | BTK 3272/4885GAA 1822/4885MEN1 2784/4885 |
| US-20090291978-A1 | Enzyme Inhibitors | HAT1, NR2E1, NR2C2 | BTK 2790/4885GAA 3209/4885MEN1 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.